NCT05312697View on ClinicalTrials.gov

Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis Imperfecta

PHASE2TerminatedINTERVENTIONAL

Enrollment

2

Participants

Timeline

Start Date

April 28, 2022

Primary Completion Date

July 7, 2022

Study Completion Date

July 7, 2022

Conditions

Osteogenesis Imperfecta

Interventions

BIOLOGICAL

Setrusumab

A fully human anti-sclerostin monoclonal antibody (mAb)

Trial Locations (1)

87106

New Mexico Clinical Research & Osteoporosis Center, Albuquerque

Sponsors

Collaborators (1)

Mereo BioPharma

All Listed Sponsors

collaborator

Mereo BioPharma

INDUSTRY

lead

Ultragenyx Pharmaceutical Inc

INDUSTRY